Figure 1. Phase contrast images of live-cells under the monitored conditions for days 
and 
after treatment.
The images have been selected using the FDA classifier that has its median FDA score on training day 
. For clearer examples of the differentiated state, we selected for the NGF without mitomycin treatment images which correspond to the 
% quantile instead of the 
% median. Small inserts show the resulting ROI for each image. The white arrows indicate outgrown neurites on day 
. The proliferative effect of both EGF and NGF treatment without mitomycin is evident from the increased ROI on day 
. Mitomycin treatment inhibits proliferation and enhances the visibility of neurites. Bar, 
m.